Hematologic toxicities of small molecule tyrosine kinase inhibitors

Nicholas A. Barber, Wais Afzal, Mojtaba Akhtari

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Small molecule tyrosine kinase inhibitors (TKIs) are potent anti-cancer targeted therapies. TKIs are considered safe and efficacious therapeutic modalities, and are generally tolerated well. However, they are associated with certain side effects including hematologic toxicities such as anemia, macrocytosis, neutropenia, thrombocytopenia, hemolytic anemia, bone marrow aplasia and necrosis. Thrombotic microangiopathy, arterial thromboembolism and splenic infarction can also occur following treatment with TKIs. Cytopenias are the most common adverse effects associated with these agents, and other hematologic toxicities are not frequent. It is essential for clinicians to monitor patients closely, and recognize those side effects as early as possible, in order to improve efficacy of small molecule TKIs and optimize outcomes. This article summarizes hematologic toxicities associated with the commonly used small molecule TKIs. It also provides practical strategies for the management of these toxicities.

Original languageEnglish (US)
Pages (from-to)203-215
Number of pages13
JournalTargeted Oncology
Volume6
Issue number4
DOIs
StatePublished - Dec 1 2011

Fingerprint

Protein-Tyrosine Kinases
Hematologic Agents
Splenic Infarction
Thrombotic Microangiopathies
Osteonecrosis
Hemolytic Anemia
Thromboembolism
Neutropenia
Thrombocytopenia
Anemia
Therapeutics
Bone Marrow
Neoplasms

Keywords

  • Adverse effects
  • Hematologic
  • Small molecule tyrosine kinase inhibitors
  • Toxicities

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Hematologic toxicities of small molecule tyrosine kinase inhibitors. / Barber, Nicholas A.; Afzal, Wais; Akhtari, Mojtaba.

In: Targeted Oncology, Vol. 6, No. 4, 01.12.2011, p. 203-215.

Research output: Contribution to journalReview article

Barber, Nicholas A. ; Afzal, Wais ; Akhtari, Mojtaba. / Hematologic toxicities of small molecule tyrosine kinase inhibitors. In: Targeted Oncology. 2011 ; Vol. 6, No. 4. pp. 203-215.
@article{9a1febf40b4a478ea3eba19acc9e351a,
title = "Hematologic toxicities of small molecule tyrosine kinase inhibitors",
abstract = "Small molecule tyrosine kinase inhibitors (TKIs) are potent anti-cancer targeted therapies. TKIs are considered safe and efficacious therapeutic modalities, and are generally tolerated well. However, they are associated with certain side effects including hematologic toxicities such as anemia, macrocytosis, neutropenia, thrombocytopenia, hemolytic anemia, bone marrow aplasia and necrosis. Thrombotic microangiopathy, arterial thromboembolism and splenic infarction can also occur following treatment with TKIs. Cytopenias are the most common adverse effects associated with these agents, and other hematologic toxicities are not frequent. It is essential for clinicians to monitor patients closely, and recognize those side effects as early as possible, in order to improve efficacy of small molecule TKIs and optimize outcomes. This article summarizes hematologic toxicities associated with the commonly used small molecule TKIs. It also provides practical strategies for the management of these toxicities.",
keywords = "Adverse effects, Hematologic, Small molecule tyrosine kinase inhibitors, Toxicities",
author = "Barber, {Nicholas A.} and Wais Afzal and Mojtaba Akhtari",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s11523-011-0202-9",
language = "English (US)",
volume = "6",
pages = "203--215",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Hematologic toxicities of small molecule tyrosine kinase inhibitors

AU - Barber, Nicholas A.

AU - Afzal, Wais

AU - Akhtari, Mojtaba

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Small molecule tyrosine kinase inhibitors (TKIs) are potent anti-cancer targeted therapies. TKIs are considered safe and efficacious therapeutic modalities, and are generally tolerated well. However, they are associated with certain side effects including hematologic toxicities such as anemia, macrocytosis, neutropenia, thrombocytopenia, hemolytic anemia, bone marrow aplasia and necrosis. Thrombotic microangiopathy, arterial thromboembolism and splenic infarction can also occur following treatment with TKIs. Cytopenias are the most common adverse effects associated with these agents, and other hematologic toxicities are not frequent. It is essential for clinicians to monitor patients closely, and recognize those side effects as early as possible, in order to improve efficacy of small molecule TKIs and optimize outcomes. This article summarizes hematologic toxicities associated with the commonly used small molecule TKIs. It also provides practical strategies for the management of these toxicities.

AB - Small molecule tyrosine kinase inhibitors (TKIs) are potent anti-cancer targeted therapies. TKIs are considered safe and efficacious therapeutic modalities, and are generally tolerated well. However, they are associated with certain side effects including hematologic toxicities such as anemia, macrocytosis, neutropenia, thrombocytopenia, hemolytic anemia, bone marrow aplasia and necrosis. Thrombotic microangiopathy, arterial thromboembolism and splenic infarction can also occur following treatment with TKIs. Cytopenias are the most common adverse effects associated with these agents, and other hematologic toxicities are not frequent. It is essential for clinicians to monitor patients closely, and recognize those side effects as early as possible, in order to improve efficacy of small molecule TKIs and optimize outcomes. This article summarizes hematologic toxicities associated with the commonly used small molecule TKIs. It also provides practical strategies for the management of these toxicities.

KW - Adverse effects

KW - Hematologic

KW - Small molecule tyrosine kinase inhibitors

KW - Toxicities

UR - http://www.scopus.com/inward/record.url?scp=84856058333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856058333&partnerID=8YFLogxK

U2 - 10.1007/s11523-011-0202-9

DO - 10.1007/s11523-011-0202-9

M3 - Review article

C2 - 22127751

AN - SCOPUS:84856058333

VL - 6

SP - 203

EP - 215

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -